Early movers: GIS, ACN, WGO, FDX, LL, LLY, PLAY, VRX, AIG, QCOM & more

Traders work on the floor of the New York Stock Exchange.
Getty Images
Traders work on the floor of the New York Stock Exchange.

Check out which companies are making headlines before the bell:

General Mills — The food producer fell a penny short of estimates with adjusted profit of 82 cents per share, with revenue also below estimates. General Mills saw revenue drop in all its retail categories, but the company did say its results are in line with its expectations.

Accenture — The firm missed estimates by 4 cents with quarterly profit of $1.28 per share, though revenue did beat forecasts due to growth at its consulting business.

Winnebago — The maker of recreational vehicles earned 32 cents per share for its latest quarter, 5 cents shy of estimates, and revenue was also short of forecasts.

FedEx — The delivery company reported adjusted quarterly profit of $2.58 per share, 7 cents above estimates, with revenue also exceeding forecasts. FedEx credits the outperformance to larger profit margins and lower costs, among other factors.

Oracle — Oracle beat estimates by 3 cents with adjusted quarterly profit of 63 cents per share, but revenue came in below forecasts. The business software company saw the strong dollar impact its results, and it predicted lower than expected numbers for the current quarter as it continues its transition from traditional software to a cloud-based subscription model.

Micron Technology — The chipmaker's shares were upgraded to "overweight" from "equal-weight" at Morgan Stanley, which said both valuation and sentiment are near a bottom. Morgan Stanley sees a potential upside of 30 percent as fundamentals stabilize.

GoDaddy — The Internet registry company filed for a 4.3 million share secondary offering. It will not receive any proceeds from the sale, which involves stockholders who currently hold shares in an entity encompassing various GoDaddy business units.

Lumber Liquidators — Goldman Sachs downgraded the flooring retailer to "sell" from "neutral," pointing to eroding fundamental trends that were in evidence even prior to this year's controversy over formaldehyde levels in China-sourced flooring material.

Dave & Buster's — BMO began coverage of the restaurant chain with an "outperform" rating, calling it an attractive long-term investment opportunity because of "concept differentiation."

Valeant Pharmaceuticals — Mizuho downgraded the drugmaker's stock to "neutral" from "buy," noting the recent unexpectedly strong reaction to the company's new deal with Walgreens. It sees less certainty about the company's ability to outperform expectations and no obvious catalyst to push the stock beyond its $130 price target.

Restoration Hardware — Guggenheim rates the home furnishings retailer a "buy" in new coverage, citing the company's "disruptive" growth platform.

Qualcomm — JPMorgan Chase upgraded the chipmaker's stock to "overweight" from "neutral," saying the stock is trading "materially low bear case" levels. The firm sees Qualcomm benefitting from diversifying away from the wireless industry and cost-cutting.

Jabil Circuit — Jabil saw its quarterly results come in 5 cents above estimates, with adjusted profit of 85 cents per share, while revenue was in line for the contract electronics manufacturer.

Pier 1 Imports — Pier 1 reported quarterly profit of 13 cents per share, 1 cent above estimates, but revenue was well below Street forecasts. The home goods retailer also slashed its 2016 earnings guidance, citing the decline of the casual in-store shopper.

AIG — AIG announced a new $3 billion share buyback program, which increases the insurance company's total remaining buyback authorization to approximately $4.3 billion.

Pandora — The online radio service's shares are getting a boost after the Copyright Royalty Board imposed a music royalty hike of 20 percent for online broadcasters, less than had been expected.

AstraZeneca — AstraZeneca struck a deal to buy 55 percent of privately held biotech company Acerta Pharma for $4 billion. The transaction gives the European drugmaker access to Acerta's new blood cancer drug, seen by AstraZeneca as having the potential for $5 billion in annual sales.

Avon Products — Avon is near a deal with Cerberus which would see the private equity firm take a nearly 17 percent stake in the cosmetics company, according to The Wall Street Journal. The deal would also see Cerberus buy 80 percent of Avon's North American business.

Eli Lilly — Lilly received FDA approval to market its diabetes treatment Basaglar, which is a copy of Sanofi's best-selling Lantus. Earlier this year, the two companies had settled a lawsuit over Lilly's right to market a copy of the drug in the US.